Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Spyre Therapeutics, Inc. - Common Stock (NQ:SYRE)

72.40 -1.25 (-1.70%)
Streaming Delayed Price Updated: 12:23 PM EDT, Jun 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Spyre Therapeutics, Inc. - Common Stock

< Previous 1 2 Next >
News headline image
Spyre Therapeutics Announces Completion of Enrollment in SKYWAY Basket Trial Evaluating SPY072 (anti-TL1A) in RA, PsA, and axSpA
From Spyre Therapeutics, Inc.
Via GlobeNewswire
News headline image
Spyre Therapeutics to Participate in Upcoming June Investor Conferences
From Spyre Therapeutics, Inc.
Via GlobeNewswire
News headline image
Maze Therapeutics Stock Still Up 180% After March Tumble. One Fund Just Disclosed Selling $3 Million in Shares ↗
Maze Therapeutics is a U.S. biotech advancing clinical-stage precision medicines for renal and metabolic diseases. 
Via The Motley Fool
News headline image
Tyra Biosciences Stock Has Soared 280% in a Year. One Fund Just Disclosed Buying More Shares ↗
Tyra Biosciences develops targeted therapies for cancer and rare diseases, leveraging proprietary technology to advance its drug pipeline. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Biotech Has a June 30 FDA Catalyst. A Fund Just Cut Its Stake by $7 Million ↗
Viridian Therapeutics develops monoclonal antibody therapies targeting serious diseases, with a primary focus on thyroid eye disease. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Obesity Drug Stock Has Jumped 60% as Phase 3 Plans Advance. A Fund Just Sold $4.7 Million ↗
This clinical-stage biotech develops oral therapeutics for chronic diseases, with a pipeline centered on metabolic and pulmonary targets. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Spyre Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
From Spyre Therapeutics, Inc.
Via GlobeNewswire
News headline image
Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $463.5 Million
From Spyre Therapeutics, Inc.
Via GlobeNewswire
News headline image
Spyre Therapeutics Announces Pricing of Upsized $403.0 Million Public Offering of Common Stock
From Spyre Therapeutics, Inc.
Via GlobeNewswire
News headline image
Spyre Therapeutics Announces Proposed Public Offering of its Common Stock
From Spyre Therapeutics, Inc.
Via GlobeNewswire
News headline image
These stocks are gapping in today's session ↗
Let's have a look at what is happening on the US markets on Monday. Below you can find the gap up and gap down stocks in today's session. 
Via Chartmill
News headline image
Spyre Announces Potential Best-in-Class SPY001 Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients
From Spyre Therapeutics, Inc.
Via GlobeNewswire
News headline image
Spyre Therapeutics to Host Conference Call to Report SPY001 Part A Induction Topline Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients on April 13, 2026
From Spyre Therapeutics, Inc.
Via GlobeNewswire
News headline image
Spyre CEO Sells $740K in Stock After 300% Surge as Key Q3 Data Nears ↗
This biotech innovator in antibody therapies for IBD reported a notable insider sale amid ongoing preclinical development efforts. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Signal or Noise: What VR Adviser's Spyre Theraputics Buy Means for Fools ↗
Spyre Therapeutics focuses on antibody therapies for inflammatory bowel disease, advancing a pipeline aimed at gastrointestinal health. 
Via The Motley Fool
News headline image
What to Make of VR Adviser's Big Ocular Therapeutix Sell-Down ↗
This ophthalmic biopharma firm develops sustained drug delivery therapies for eye diseases, targeting both U.S. and global markets. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Spyre Announces Acceleration of Expected Topline Readout of SKYWAY Rheumatoid Arthritis Sub-study to Q3 2026
From Spyre Therapeutics, Inc.
Via GlobeNewswire
News headline image
VR Adviser Adds Over 1 Million Savara Shares ↗
This clinical-stage biotech develops inhaled therapies for rare respiratory diseases, with its lead candidate in Phase III trials. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Spyre Therapeutics to Participate in Upcoming March Investor Conferences
From Spyre Therapeutics, Inc.
Via GlobeNewswire
News headline image
From Sizable Stake to Zero: The Likely Reason Why Agios Shares Lost a $94 Million Backer ↗
Agios Pharmaceuticals develops therapies for rare blood disorders, anchored by its PYRUKYND franchise and early-stage clinical programs. 
Via The Motley Fool
News headline image
Viridian Therapeutics Stock Up 75%, but One Fund Just Sold Off Its $69 Million Stake ↗
Viridian Therapeutics develops monoclonal antibody therapies targeting rare diseases, with a focus on thyroid eye disease treatments. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Spyre Therapeutics Stock Surges This Past Year as $10.5 Million Buy Lifts Stake to $78 Million ↗
Spyre Therapeutics develops preclinical monoclonal antibody therapies targeting inflammatory bowel disease and related conditions. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Biotech Fund Dumps 1.85 Million Centessa Shares as Stock Jumps Over 50% ↗
Centessa Pharmaceuticals develops clinical-stage therapies for rare and serious diseases, leveraging a portfolio approach in biopharma. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Biotech Fund Dumps $84 Million of Nuvalent With Stock Up 29% ↗
Nuvalent develops targeted cancer therapies, advancing clinical candidates for patients with limited treatment options in oncology. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Spyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
From Spyre Therapeutics, Inc.
Via GlobeNewswire
News headline image
Spyre Therapeutics Announces Presentations at the 21st ECCO Congress Supporting Differentiated Profile of SPY003 and Novel Animal Studies Demonstrating Superiority of Combination Approach
From Spyre Therapeutics, Inc.
Via GlobeNewswire
News headline image
Spyre Therapeutics Poised for Transformational 2026 With Six Expected Proof-of-Concept Readouts Beginning in Q2
From Spyre Therapeutics, Inc.
Via GlobeNewswire
Spyre Therapeutics' CEO Sells 15,000 Shares ↗
This biotech innovator in antibody therapies for inflammatory bowel disease reported a notable insider sale, according to a recent SEC filing. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Spyre Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
From Spyre Therapeutics, Inc.
Via GlobeNewswire
News headline image
Spyre Therapeutics Announces Positive Interim Phase 1 Results for SPY003, Its Novel, Half-Life Extended anti-IL-23 Antibody
From Spyre Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.